J Endocr Surg.  2019 Sep;19(3):76-84. 10.16956/jes.2019.19.3.76.

Association between BRAF(V600E) Mutations and Clinicopathological Features of Papillary Thyroid Microcarcinoma (PTMC)

• Lee SM
• Lee CR
• Kang SW
• Lee J
• Jeong JJ
• Nam KH
• Chung WY
• Park CS

• KMID: 2458705
• DOI: http://doi.org/10.16956/jes.2019.19.3.76

Abstract

PURPOSE
In this study, the relationship between the BRAF(V600E) mutation and the clinicopathological features of papillary thyroid microcarcinoma (PTMC) was examined in a single center.
METHODS
From January 2011 to December 2012, a total of 911 patients with PTMC who underwent thyroidectomy at Severance Hospital, Korea were enrolled in this study. The status of BRAF(V600E) mutation was assessed in thyroid fine-needle aspiration specimens by real-time polymerase chain reaction amplification prior to thyroidectomy. The associations between BRAF(V600E) mutation status and clinicopathological features of PTMC were examined.
RESULTS
The overall prevalence of the BRAF(V600E) mutations was 78.8% (717/911). Chi-square analysis revealed that BRAF(V600E) mutations were significantly associated with the male sex, lateral neck node metastasis, and several risk factors. And the age, tumor size, extent of surgery, multiplicity, bilaterality, central node metastasis, and distant metastasis were not associated with BRAF(V600E) mutation. Multivariate analysis showed that capsular invasion and lateral neck node metastasis were significantly associated with BRAF(V600E) mutations. In particular, lateral neck node metastasis showed negative correlation with BRAF(V600E) mutations. And the recurrence rate and disease-free survival were not associated with BRAF(V600E) mutation status.
CONCLUSION
BRAF(V600E) mutations in PTMC was associated with presence of capsular invasion and absence of lateral neck node metastasis. However, BRAF(V600E) mutations could not serve as a prognostic factor that affected the recurrence of PTMC in our study.

Keyword

Papillary thyroid cancer; Mutation; Prognosis

MeSH Terms

Biopsy, Fine-Needle
Disease-Free Survival
Humans
Korea
Male
Multivariate Analysis
Neck
Neoplasm Metastasis
Prevalence
Prognosis
Real-Time Polymerase Chain Reaction
Recurrence
Risk Factors
Thyroid Gland*
Thyroidectomy

Figure

• 

  Fig. 1 Disease-free survival according to the BRAF mutation status(P=0.350).

Reference

1. DeLellis RA, Lloyd RV, Heitz PU, Eng C. Pathology and Genetics of Tumours of Endocrine Organs. Lyon: International Agency for Research on Cancer (IARC);2004.

2. Roti E, degli Uberti EC, Bondanelli M, Braverman LE. Thyroid papillary microcarcinoma: a descriptive and meta-analysis study. Eur J Endocrinol. 2008; 159:659–673.

3. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016; 26:1–133.

4. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417:949–954.

5. Song YS, Lim JA, Park YJ. Mutation profile of well-differentiated thyroid cancer in Asians. Endocrinol Metab (Seoul). 2015; 30:252–262.

6. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007; 28:742–762.

7. Mathur A, Weng J, Moses W, Steinberg SM, Rahbari R, Kitano M, et al. A prospective study evaluating the accuracy of using combined clinical factors and candidate diagnostic markers to refine the accuracy of thyroid fine needle aspiration biopsy. Surgery. 2010; 148:1170–1176.

8. Xing M. BRAF mutation and thyroid cancer recurrence. J Clin Oncol. 2015; 33:2482–2483.

9. Xing M, Alzahrani AS, Carson KA, Shong YK, Kim TY, Viola D, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol. 2015; 33:42–50.

10. Kim SJ, Lee KE, Myong JP, Park JH, Jeon YK, Min HS, et al. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg. 2012; 36:310–317.

11. Kwak JY, Kim EK, Chung WY, Moon HJ, Kim MJ, Choi JR. Association of BRAF^V600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. Radiology. 2009; 253:854–860.

12. Choi SY, Park H, Kang MK, Lee DK, Lee KD, Lee HS, et al. The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors. World J Surg Oncol. 2013; 11:291.

13. Li J, Zhang S, Zheng S, Zhang D, Qiu X. The BRAF V600E mutation predicts poor survival outcome in patients with papillary thyroid carcinoma: a meta analysis. Int J Clin Exp Med. 2015; 8:22246–22253.

14. Korea Central Cancer Registry, National Cancer Control Institute. Annual report of cancer statistics in Korea in 2016. Sejong: Ministry of Health and Welfare;2018.

15. Ahn HS, Kim HJ, Welch HG. Korea's thyroid-cancer “epidemic”--screening and overdiagnosis. N Engl J Med. 2014; 371:1765–1767.

16. Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf). 2005; 63:588–593.

17. Sun Y, Shi C, Shi T, Yu J, Li Z. Correlation between the BRAF(v600E) gene mutation and factors influencing the prognosis of papillary thyroid microcarcinoma. Int J Clin Exp Med. 2015; 8:22525–22528.

18. Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, et al. BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J. 2009; 56:89–97.

19. Goutas N, Vlachodimitropoulos D, Bouka M, Lazaris AC, Nasioulas G, Gazouli M. BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort. Anticancer Res. 2008; 28:305–308.

20. Xing M. BRAF V600E mutation and papillary thyroid cancer. JAMA. 2013; 310:535.

21. Kim SK, Song KH, Lim SD, Lim YC, Yoo YB, Kim JS, et al. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis. Thyroid. 2009; 19:137–141.

22. Guan H, Ji M, Bao R, Yu H, Wang Y, Hou P, et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab. 2009; 94:1612–1617.

23. Hong AR, Lim JA, Kim TH, Choi HS, Yoo WS, Min HS, et al. The frequency and clinical implications of the BRAF(V600E) mutation in papillary thyroid cancer patients in Korea over the past two decades. Endocrinol Metab (Seoul). 2014; 29:505–513.

24. Jung CK, Little MP, Lubin JH, Brenner AV, Wells SA Jr, Sigurdson AJ, et al. The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab. 2014; 99:E276–85.

25. Liu C, Chen T, Zeng W, Wang S, Xiong Y, Liu Z, et al. Reevaluating the prognostic significance of male gender for papillary thyroid carcinoma and microcarcinoma: a SEER database analysis. Sci Rep. 2017; 7:11412.

26. Kim MJ, Lee SG, Kim K, Lee CR, Kang SW, Lee J, et al. Current trends in the features of male thyroid cancer: retrospective evaluation of their prognostic value. Medicine (Baltimore). 2019; 98:e15559.

27. Pacini F. Management of papillary thyroid microcarcinoma: primum non nocere! J Clin Endocrinol Metab. 2013; 98:1391–1393.

28. Kwak JY, Kim EK, Kim MJ, Son EJ, Chung WY, Park CS, et al. Papillary microcarcinoma of the thyroid: predicting factors of lateral neck node metastasis. Ann Surg Oncol. 2009; 16:1348–1355.

29. Wu X, Li B, Zheng C, He X. Predicting factors of lateral neck lymph node metastases in patients with papillary thyroid microcarcinoma. Medicine (Baltimore). 2019; 98:e16386.

30. Kim SK, Woo JW, Lee JH, Park I, Choe JH, Kim JH, et al. Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma. Surgery. 2015; 158:1500–1511.

31. Moon HJ, Kim EK, Chung WY, Shin DY, Kwak JY. BRAF mutation in fine-needle aspiration specimens as a potential predictor for persistence/recurrence in patients with classical papillary thyroid carcinoma larger than 10 mm at a BRAF mutation prevalent area. Head Neck. 2015; 37:1432–1438.

32. Ma YJ, Deng XL, Li HQ. BRAF(V⁶⁰⁰E) mutation and its association with clinicopathological features of papillary thyroid microcarcinoma: a meta-analysis. J Huazhong Univ Sci Technolog Med Sci. 2015; 35:591–599.

33. Chung KW, Yang SK, Lee GK, Kim EY, Kwon S, Lee SH, et al. Detection of BRAF^V600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin Endocrinol (Oxf). 2006; 65:660–666.